Publishing research using ab2399? Please let us know so that we can cite the reference in this datasheet.

ab2399 has been referenced in 7 publications.

  • Yi JM  et al. Dual targeting of microtubule and topoisomerase II by a-carboline derivative YCH337 for tumor proliferation and growth inhibition. Oncotarget 6:8960-73 (2015). Human . PubMed: 25840421
  • Ghadimi MP  et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res 18:2545-57 (2012). WB ; Human . PubMed: 22407831
  • Juvekar A  et al. Bortezomib Induces Nuclear Translocation of I{kappa}B{alpha} Resulting in Gene-Specific Suppression of NF-{kappa}B-Dependent Transcription and Induction of Apoptosis in CTCL. Mol Cancer Res 9:183-94 (2011). PubMed: 21224428
  • Lopergolo A  et al. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Br J Cancer 100:739-46 (2009). WB ; Human . PubMed: 19223905
  • Mokhtari D  et al. Overexpression of the nuclear factor-?B subunit c-Rel protects against human islet cell death in vitro. Am J Physiol Endocrinol Metab 297:E1067-77 (2009). PubMed: 19706790
  • Wang SW  et al. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther 7:350-60 (2008). WB ; Mouse . PubMed: 18281518
  • Gyrd-Hansen M  et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 10:1309-17 (2008). WB . PubMed: 18931663

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"